An antibody has tips that find a target and a stem that can connect to other parts of the immune system. Two antibodies can reach the same target and do different jobs.
A typical immunoglobulin G (IgG) antibody has two heavy and two light chains held together by molecular interactions and disulfide bonds. At each arm tip, variable regions from a heavy and a light chain together form a binding site; its sequence and three-dimensional shape influence what it recognises. Fab (fragment antigen-binding) names an arm containing the binding site and its associated constant domains, so it is not simply another word for the variable region. Fc (fragment crystallizable, a name that comes from an experimental property) names the remaining stem, built from CH2 and CH3 domains of both heavy chains in the familiar IgG description. Hinge flexibility changes how the arms are arranged. A drawn Y is a simplification: some natural and engineered formats omit familiar parts.
Fc can interact with immune-cell receptors and with complement, but compatible effectors, target arrangement and other conditions decide whether killing, engulfment or complement damage follows, so Fc is not an automatic kill command. Binding and effector contributions are separate and the finished molecule needs testing. Nimmerjahn and Ravetch (2005) showed in mouse experiments that IgG subclasses differ in the ratio of their binding to activating and inhibitory Fc receptors, which predicted in vivo activity; that is not a universal ranking of human antibody performance. An isotype is a heavy-chain class (see the isotypes and Fc silencing record). Structure alone does not identify the producing cell or establish what the antibody recognises.
The epitope is the molecular feature recognised and can be a folded protein surface or another accessible feature, not necessarily a short fragment displayed by HLA. Binding is measured against a defined antigen preparation and antibody concentration, sometimes in nanomoles per litre, and it matters whether the test used purified protein or intact cells, because folding, accessibility and multiple binding sites change the result. A concentration or fluorescence signal alone is not an affinity. Fc-receptor and complement interactions are tested separately from target binding, and neither binding nor a laboratory effector result establishes clinical benefit or safety. A blocking antibody, an antibody-drug conjugate and a bispecific format can share a target and still act differently.
Shares B cell, Antibody and the tag education-immunology-2026-11.
Shares Epitope and the tag education-immunology-2026-11.
Shares Epitope and the tag education-immunology-2026-11.
Shares Antibody isotypes and Fc silencing, Antibody-guided effector mechanisms (ADCC, ADCP, CDC).
Shares Antibody isotypes and Fc silencing, Fc engineering / effector function, Antibody.
Shares Antibody isotypes and Fc silencing, Antibody-guided effector mechanisms (ADCC, ADCP, CDC).
Shares Antibody isotypes and Fc silencing, Antibody-guided effector mechanisms (ADCC, ADCP, CDC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/